New immune cell therapy takes on virus after transplant
NCT ID NCT07368634
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tests a new treatment for Epstein-Barr virus (EBV) that can occur after a stem cell transplant. The treatment uses specially engineered immune cells (EBV-TCR-T cells) to find and destroy virus-infected cells. Up to 18 adult patients who have persistent EBV despite standard care will receive up to three infusions. The main goal is to check safety, but researchers will also see if the virus clears from the blood.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- EBV-TCR-T cells (engineered immune cells designed to target and kill Epstein-Barr virus-infected cells)
- What this could lead to
- If successful, this could offer a new treatment option for controlling Epstein-Barr virus after stem cell transplants, potentially preventing serious complications like lymphoproliferative disorders.
- What could go wrong
- This is a very early, small trial (18 participants) testing safety first. The treatment may not work, and there are risks like cytokine release syndrome or other infusion reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPSTEIN-BARR VIRUS INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chinese PLA General Hospital
RECRUITINGBeijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can cord blood t cells be trained to stop viral infections after transplant?
- Can a new drug combo shield young hearts from transplant complications?
- Can a nanoparticle vaccine stop the virus behind mono and some cancers?
- Suicide Gene-Equipped t cells aim to make stem cell transplants safer
- Can 'Supercharged' donor cells beat viruses that drugs Can't?
- Donor immune cells take on tough viruses in transplant patients